IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
Sponsor: Altimmune, Inc.
A PHASE2 clinical study on Non-Alcoholic Steatohepatitis (NASH), this trial is completed. The trial is conducted by Altimmune, Inc. and has accumulated 10 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Dec 2023 [monthly]
Recruiting PHASE2
First recorded
Jul 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Altimmune, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .